Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 38347536)

  • 1. Superbinder based phosphoproteomic landscape revealed PRKCD_pY313 mediates the activation of Src and p38 MAPK to promote TNBC progression.
    Deng Y; Hou Z; Li Y; Yi M; Wu Y; Zheng Y; Yang F; Zhong G; Hao Q; Zhai Z; Wang M; Ma X; Kang H; Ji F; Dong C; Liu H; Dai Z
    Cell Commun Signal; 2024 Feb; 22(1):115. PubMed ID: 38347536
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dasatinib inhibits c-src phosphorylation and prevents the proliferation of Triple-Negative Breast Cancer (TNBC) cells which overexpress Syndecan-Binding Protein (SDCBP).
    Qian XL; Zhang J; Li PZ; Lang RG; Li WD; Sun H; Liu FF; Guo XJ; Gu F; Fu L
    PLoS One; 2017; 12(1):e0171169. PubMed ID: 28141839
    [TBL] [Abstract][Full Text] [Related]  

  • 3. UM-164: A Potent c-Src/p38 Kinase Inhibitor with In Vivo Activity against Triple-Negative Breast Cancer.
    Gilani RA; Phadke S; Bao LW; Lachacz EJ; Dziubinski ML; Brandvold KR; Steffey ME; Kwarcinski FE; Graveel CR; Kidwell KM; Merajver SD; Soellner MB
    Clin Cancer Res; 2016 Oct; 22(20):5087-5096. PubMed ID: 27154914
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Global phosphotyrosine proteomics identifies PKCδ as a marker of responsiveness to Src inhibition in colorectal cancer.
    McKinley ET; Liu H; McDonald WH; Luo W; Zhao P; Coffey RJ; Hanks SK; Manning HC
    PLoS One; 2013; 8(11):e80207. PubMed ID: 24260357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dasatinib attenuates overexpression of Src signaling induced by the combination treatment of veliparib plus carboplatin in triple-negative breast cancer.
    Sun Y; Lin X; Aske JC; Ye P; Williams C; Abramovitz M; Leyland-Jones BR
    Cancer Chemother Pharmacol; 2019 Dec; 84(6):1241-1256. PubMed ID: 31541266
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of Akt/mTOR pathway overcomes intrinsic resistance to dasatinib in triple-negative breast cancer.
    Haga Y; Higashisaka K; Yang L; Sekine N; Lin Y; Tsujino H; Nagano K; Tsutsumi Y
    Biochem Biophys Res Commun; 2020 Dec; 533(4):672-678. PubMed ID: 33036754
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cetuximab PET delineated changes in cellular distribution of EGFR upon dasatinib treatment in triple negative breast cancer.
    McKnight BN; Kim S; Boerner JL; Viola NT
    Breast Cancer Res; 2020 Apr; 22(1):37. PubMed ID: 32295603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. c-Src inhibitor selectively inhibits triple-negative breast cancer overexpressed Vimentin in vitro and in vivo.
    Lou L; Yu Z; Wang Y; Wang S; Zhao Y
    Cancer Sci; 2018 May; 109(5):1648-1659. PubMed ID: 29575318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Role and Mechanism of CRT0066101 as an Effective Drug for Treatment of Triple-Negative Breast Cancer.
    Liu Y; Wang Y; Yu S; Zhou Y; Ma X; Su Q; An L; Wang F; Shi A; Zhang J; Chen L
    Cell Physiol Biochem; 2019; 52(3):382-396. PubMed ID: 30845378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tyrosine kinase SRC-induced YAP1-KLF5 module regulates cancer stemness and metastasis in triple-negative breast cancer.
    Zou H; Luo J; Guo Y; Tong T; Liu Y; Chen Y; Xiao Y; Ye L; Zhu C; Deng L; Wang B; Pan Y; Li P
    Cell Mol Life Sci; 2023 Jan; 80(2):41. PubMed ID: 36633714
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.
    Adams BD; Wali VB; Cheng CJ; Inukai S; Booth CJ; Agarwal S; Rimm DL; Győrffy B; Santarpia L; Pusztai L; Saltzman WM; Slack FJ
    Cancer Res; 2016 Feb; 76(4):927-39. PubMed ID: 26676753
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PRKCQ promotes oncogenic growth and anoikis resistance of a subset of triple-negative breast cancer cells.
    Byerly J; Halstead-Nussloch G; Ito K; Katsyv I; Irie HY
    Breast Cancer Res; 2016 Sep; 18(1):95. PubMed ID: 27663795
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alcohol promotes migration and invasion of triple-negative breast cancer cells through activation of p38 MAPK and JNK.
    Zhao M; Howard EW; Parris AB; Guo Z; Zhao Q; Yang X
    Mol Carcinog; 2017 Mar; 56(3):849-862. PubMed ID: 27533114
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Evaluation of a Novel Orally Available SRC/Raf/VEGFR2 Inhibitor, SKLB646, in the Treatment of Triple-Negative Breast Cancer.
    Zheng MW; Zhang CH; Chen K; Huang M; Li YP; Lin WT; Zhang RJ; Zhong L; Xiang R; Li LL; Liu XY; Wei YQ; Yang SY
    Mol Cancer Ther; 2016 Mar; 15(3):366-78. PubMed ID: 26721945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. COL8A1 facilitates the growth of triple-negative breast cancer via FAK/Src activation.
    Sato F; Sagara A; Tajima K; Miura S; Inaba K; Ando Y; Oku T; Murakami T; Kato Y; Yumoto T
    Breast Cancer Res Treat; 2022 Jul; 194(2):243-256. PubMed ID: 35624176
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
    Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
    Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of a Triple Drug Combination That Is Synergistically Cytotoxic for Triple-Negative Breast Cancer Cells Using a Novel Combination Discovery Approach.
    Ahmad S; He Q; Williams KP; Scott JE
    SLAS Discov; 2020 Sep; 25(8):923-938. PubMed ID: 32441190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PKMYT1 Promotes Epithelial-Mesenchymal Transition Process in Triple-Negative Breast Cancer by Activating Notch Signaling.
    Li B; Huang L; Ruan J
    Rev Invest Clin; 2024; 76(1):45-59. PubMed ID: 38442372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Src Kinase Is Biphosphorylated at Y416/Y527 and Activates the CUB-Domain Containing Protein 1/Protein Kinase C δ Pathway in a Subset of Triple-Negative Breast Cancers.
    Nelson LJ; Wright HJ; Dinh NB; Nguyen KD; Razorenova OV; Heinemann FS
    Am J Pathol; 2020 Feb; 190(2):484-502. PubMed ID: 31843498
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Calycosin inhibits triple-negative breast cancer progression through down-regulation of the novel estrogen receptor-α splice variant ER-α30-mediated PI3K/AKT signaling pathway.
    Li Y; Hu S; Chen Y; Zhang X; Gao H; Tian J; Chen J
    Phytomedicine; 2023 Sep; 118():154924. PubMed ID: 37393829
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.